Loading
Endoplasmic Reticulum Stress and Disease / Pancreatic Function and Diabetes · Journal article
Science Translational Medicine · September 2, 2026
Encouraging direction, but not yet definitive.
Loss of ALDH3B2 function induces human pancreatic duct cells to transdifferentiate into functional insulin-secreting β-like cells in vitro and in vivo in mice. This identifies a potential therapeutic target for β-cell regeneration in diabetes, but remains a preclinical proof-of-concept requiring further validation and optimization before clinical translation.
Functional genomics discovery study with in vitro and in vivo validation. Human pancreatic duct cell lines, primary human pancreatic duct cells, and streptozotocin-induced diabetic mice. Intervention: ALDH3B2 loss of function (CRISPR-mediated or knockdown inferred).
ALDH3B2 loss of function transdifferentiates human pancreatic duct cells into β-like cells Transdifferentiated cells showed substantially increased expression of β cell marker genes Transdifferentiated cells secreted insulin in response to glucose
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
A single-centre, mechanistic study identifying a gene target for β-cell transdifferentiation with proof-of-concept in primary human cells and mouse transplantation, but lacking human clinical data and requiring confirmation in larger systems.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Replenishment of pancreatic β cells is key to a cure for diabetes. β cell regeneration is achieved predominantly by self-replication, especially in rodents, but it was also shown that pancreatic duct cells can transdifferentiate into β cells. How pancreatic duct cells are transdifferentiated and whether we can manipulate transdifferentiation to replenish β cell mass are not well understood. Using a genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screen, we found that the loss of function of aldehyde dehydrogenase family 3 member B2 ( ALDH3B2 ) was sufficient to transdifferentiate cell line–based and human pancreatic duct cells into functional β-like cells. The transdifferentiated cells had substantially increased the expression of β cell marker genes, secreted insulin in response to glucose, and lowered blood glucose to near normal for 6 weeks after transplantation into streptozotocin-induced diabetic mice under the kidney capsule. Our study identifies a gene that could potentially be targeted in human pancreatic duct cells to replenish β cell mass for diabetes therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.